BridgeMD
New treatment option for Atherosclerotic Cardiovascular Disease
Official title Pelacarsen Roll-over Extension Program
ClinicalTrials.gov ID: NCT06875973
What this study is testing
What is Pelacarsen (TQJ230)?
Pelacarsen (TQJ230) is an investigational medicine, given as a monthly injection under the skin, being studied as a potential treatment for atherosclerotic cardiovascular disease.
Also referred to as TQJ230.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 100
You may be able to join if
- Participants who have provided informed consent prior to initiation of any study-specific activities/procedures.
- Participants who have completed the parent study and received the assigned study treatment at the time of its completion
You likely can't join if
- Participants who permanently discontinued the study treatment as mandated per protocol or due to adverse events in the parent study
- Any medical condition(s) in the investigator's opinion that may put the participant at risk or interfere with the study participation
- Participants who are receiving another investigational drug or device before the open-label treatment period
- Participants who have a known sensitivity to the study drug and are deemed as unsuited for the study by the investigator Other protocol-defined...
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
- Little Rock, Arkansas, United States
- Beverly Hills, California, United States
- Canoga Park, California, United States
- Covina, California, United States
- Garden Grove, California, United States
- Irvine, California, United States
- Long Beach, California, United States
- Los Angeles, California, United States
- Northridge, California, United States
- Stanford, California, United States
- Boca Raton, Florida, United States
- Cape Coral, Florida, United States
- Fort Lauderdale, Florida, United States
- Hialeah, Florida, United States
- Hollywood, Florida, United States
- Miami, Florida, United States
- Miami Lakes, Florida, United States
- Miramar, Florida, United States
- Palm Springs, Florida, United States
+ 52 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States; Little Rock, Arkansas, United States; Beverly Hills, California, United States; Canoga Park, California, United States; Covina, California, United States; Garden Grove, California, United States and 66 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.